• 6 May 2019

    Index provided a status update on the patient recruitment in the CONDUCT study. “With only 10 patients left to enrol we estimate that the patient recruitment will be completed during the month of June at the latest,” said Peter Zerhouni, CEO of InDex Pharmaceuticals.

  • 2 May 2019

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) announced today top-line efficacy data for its NOX1/4 inhibitor GKT831 Phase 2 trial in primary biliary cholangitis (PBC). In a pre-defined patient population with an estimated liver fibrosis stage of F3 or higher, GKT831 achieved a 22% reduction in liver stiffness compared to a 4% increase for placebo (p=0.038). The top-line data provide a clinical proof of concept for GKT831 and highlight its potential as an anti-fibrotic therapy in the liver and other organs. Further analyses are ongoing and the full results will be submitted for presentation at an upcoming international liver conference.

  • 30 April 2019

    Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces that results from the first-in-human single dose DSR (Direct Sodium Removal) proof-of-concept study for volume overload in heart failure have been selected for oral presentation in the late-breaking abstract session at Heart Failure 2019 on 27 May 2019. Heart Failure 2019 will be held from 25 to 28 May 2019 in Athens, Greece and is the 6th World Congress on Acute Heart Failure organised by the Heart Failure Association of the European Society of Cardiology.

  • 25 April 2019

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today provided a corporate update, and reported cash and cash equivalents of 7.3 million, at March 31, 2019.

  • 12 April 2019

    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering of 5,670,000 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 2,130,000 shares of common stock, and accompanying Class A warrants to purchase 3,900,000 shares of its common stock at a price to the public of $11.00 per share and accompanying Class A warrant (or $10.999 per pre-funded warrant and accompanying Class A warrant). X4’s gross proceeds from this offering are expected to be approximately $85.8 million, before deducting underwriting discounts and estimated offering expenses. All of the securities in the offering are being sold by X4. The offering is expected to close on or about April 16, 2019, subject to customary closing conditions.